Bacterin reports results of two-year study for OsteoSponge

Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, reported results of a two-year study for OsteoSponge®.

Used in conjunction with the patients' own bone marrow aspirate, OsteoSponge is a highly effective osteoinductive and osteoconductive bone scaffold that aids in spinal fusion. The study was conducted in collaboration with researchers at the Salt Lake Orthopaedic Clinic, Spine Surgery of Salt Lake City.

The two-year post-operative, clinical data showed OsteoSponge to be equivalent to rhBMP-2 in achieving an interbody fusion based upon radiographic assessment, CT scans, and quality of life outcomes. Additionally, patients receiving the OsteoSponge graft reported statistically significant less leg pain at one year relative to the rhBMP-2 group.

"Since OsteoSponge has been released, surgeons have used our bone graft implants more than 100,000 times, and this latest study further validates its effectiveness in spinal fusion surgery," said Guy Cook, Bacterin's chairman and CEO. "Surgeons noted our product's unique handling properties, ability to irrigate the site, and quick insertion of the OsteoSponge scaffold into the PEEK cage."

This study, which evaluated the effectiveness of Bacterin's OsteoSponge allograft for use in lumbar spinal fusion and entitled, "Lumbar Interbody Fusion with OsteoSponge Demineralized Allograft in a PEEK Cage Compared to Fusion with rhBMP-2: Long Term Post-Operative Assessment," was presented at EuroSpine 2011 in Milan, Italy last week. The abstract of this presentation was published in European Spine Journal (Volume 20, Supplement 4, 421-464).

The study has also been accepted for presentation at the 2012 AAOS Annual Meeting in San Francisco, California on February 7-11, 2011.

SOURCE Bacterin International, Inc.